Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

PureTech Health Inks Deal with Boehringer Ingelheim for Immuno-Oncology

PureTech Health signed a research collaboration deal with Germany’s Boehringer Ingelheim to develop novel product candidates using the Boston-based and London-listed company’s proprietary lymphatic targeting technology for immune modulation.

Read More »

Catalent entering gene therapy market via Paragon buy

Catalent Inc. will buy privately held Paragon Bioservices Inc. for $1.2 billion in cash, bolstering the contract drugmaker’s capabilities to make gene therapy drugs for biotech clients.

Read More »

Bristol-Myers shareholders approve Celgene takeover

Bristol-Myers Squibb’s shareholders voted to approve the drugmaker’s $74 billion takeover of Celgene despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Read More »

Novartis, Amgen in dispute over migraine drug partnership

Swiss drugmaker Novartis AG sued Amgen Inc., accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.

Read More »

Precision BioSciences Launches IPO to Raise $126.4 Million

Durham, N.C.-based Precision BioSciences set the company’s initial public offering price at $16 per share, raising $126.4 million.

Read More »

Top Bristol-Myers shareholder comes out against $74 billion Celgene deal

Bristol-Myers Squibb Co.’s top shareholder Wellington Management does not support the U.S. drugmaker’s $74 billion deal to buy biotech Celgene Corp., imperiling what would be the largest pharmaceutical acquisition of all time.

Read More »

Sarepta to buy Myonexus in gene therapy push

Sarepta Therapeutics will buy privately held gene therapy company Myonexus Therapeutics for $165 million, moving deeper into an emerging and lucrative field within the biotech sector.

Read More »

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Amgen Inc. said a U.S. jury confirmed the validity of patents on the biotech company’s cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc. and Sanofi SA.

Read More »

5AM Ventures Closes $497M for Its Sixth Biotech Fund

5AM Ventures raised a total of $497 million for two more funds.

Read More »

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

AbbVie Inc., along with Teneobio Inc. and that company’s affiliate TeneoOne Inc., announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom